Vanguard Global Advisers
TRDA icon

Vanguard Global Advisers’s Entrada Therapeutics TRDA Stock Holding History

Vanguard Global Advisers’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.9K Sell
8,812
-9,586
-52% -$91.9K ﹤0.01% 2972
2026
Q1 		$232K Buy
+18,398
New +$211K ﹤0.01% 2363

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Vanguard Global Advisers's TRDA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Entrada Therapeutics (TRDA) stake by 52% in Q2 2026, selling an estimated $91.9K and leaving 8,812 shares worth $64.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

Vanguard Global Advisers first reported a position in TRDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $232K in Q1 2026. 127 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Vanguard Global Advisers held 8,812 shares of Entrada Therapeutics worth $64.9K as of Q2 2026.
  • Vanguard Global Advisers sold 9,586 Entrada Therapeutics shares in Q2 2026, an estimated $91.9K.
  • Entrada Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2972 holding.
  • Vanguard Global Advisers first reported a position in Entrada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Entrada Therapeutics position peaked at $232K in Q1 2026.
  • 127 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.